JP2024521706A5 - - Google Patents
Info
- Publication number
- JP2024521706A5 JP2024521706A5 JP2023571805A JP2023571805A JP2024521706A5 JP 2024521706 A5 JP2024521706 A5 JP 2024521706A5 JP 2023571805 A JP2023571805 A JP 2023571805A JP 2023571805 A JP2023571805 A JP 2023571805A JP 2024521706 A5 JP2024521706 A5 JP 2024521706A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- group
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191631P | 2021-05-21 | 2021-05-21 | |
| US63/191,631 | 2021-05-21 | ||
| PCT/US2022/030227 WO2022246177A1 (en) | 2021-05-21 | 2022-05-20 | Axl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024521706A JP2024521706A (ja) | 2024-06-04 |
| JP2024521706A5 true JP2024521706A5 (enExample) | 2025-05-27 |
| JP7843299B2 JP7843299B2 (ja) | 2026-04-09 |
Family
ID=82115693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571805A Active JP7843299B2 (ja) | 2021-05-21 | 2022-05-20 | Ａｘｌ化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240246967A1 (enExample) |
| EP (1) | EP4341261A1 (enExample) |
| JP (1) | JP7843299B2 (enExample) |
| CN (1) | CN117295741A (enExample) |
| TW (1) | TW202313602A (enExample) |
| WO (1) | WO2022246177A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) * | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20260115190A1 (en) | 2022-09-14 | 2026-04-30 | Arcus Biosciences, Inc. | Dispersions of etrumadenant |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240425497A1 (en) | 2023-05-05 | 2024-12-26 | Arcus Biosciences, Inc. | Cbl-b Inhibitors and Methods of Use Thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024249894A2 (en) | 2023-06-02 | 2024-12-05 | Arcus Biosciences, Inc. | Biomarkers for predicting cancer treatment efficacy |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025137370A1 (en) * | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| SG11201805506YA (en) | 2016-01-08 | 2018-07-30 | Arcus Biosciences Inc | Modulators of 5'-nucleotidase, ecto and the use thereof |
| EP3518934A4 (en) | 2016-10-03 | 2020-06-24 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| JP7150712B2 (ja) | 2016-11-18 | 2022-10-11 | アーカス バイオサイエンシズ インコーポレイティド | Ｃｄ７３媒介免疫抑制の阻害剤 |
| TWI781136B (zh) | 2017-01-20 | 2022-10-21 | 美商阿克思生物科學有限公司 | 用於治療癌症相關病症之唑嘧啶 |
| WO2018204661A1 (en) | 2017-05-05 | 2018-11-08 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| WO2020023846A1 (en) | 2018-07-27 | 2020-01-30 | Arcus Biosciences, Inc. | Pyridone a2r antagonists |
| WO2020046813A1 (en) | 2018-08-27 | 2020-03-05 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| WO2020102646A2 (en) | 2018-11-16 | 2020-05-22 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| CN113166139A (zh) * | 2018-11-22 | 2021-07-23 | 百济神州有限公司 | 作为HPK1抑制剂的吡咯并[2,3-b]吡啶及其用途 |
| CN114206332B (zh) | 2019-06-04 | 2024-08-23 | 艾库斯生物科学有限公司 | 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 |
| TWI848141B (zh) * | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| US20230024438A1 (en) | 2019-12-04 | 2023-01-26 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha |
| IL295569B1 (en) | 2020-03-19 | 2026-04-01 | Arcus Biosciences Inc | Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2ALPHA |
-
2022
- 2022-05-20 WO PCT/US2022/030227 patent/WO2022246177A1/en not_active Ceased
- 2022-05-20 EP EP22731889.6A patent/EP4341261A1/en active Pending
- 2022-05-20 CN CN202280034430.8A patent/CN117295741A/zh active Pending
- 2022-05-20 JP JP2023571805A patent/JP7843299B2/ja active Active
- 2022-05-20 TW TW111118926A patent/TW202313602A/zh unknown
- 2022-05-20 US US18/555,963 patent/US20240246967A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521712A5 (enExample) | ||
| JP7203964B2 (ja) | 統合的ストレス経路のプロドラッグ調節剤 | |
| JP2022535120A5 (enExample) | ||
| TWI838350B (zh) | 抗癌劑 | |
| JP2016506916A5 (enExample) | ||
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2021523112A5 (enExample) | ||
| CN105683201B (zh) | 新的含n‑杂环碳烯配体的金(iii)络合物、合成及其在癌症治疗和硫醇检测中的应用 | |
| JP2020510032A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2022507065A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| JP2025525364A5 (enExample) | ||
| RU2015141772A (ru) | Новые соединения и композиции для ингибирования fasn | |
| JP2019515952A5 (enExample) | ||
| JP2012158602A5 (enExample) | ||
| JP2017517548A5 (enExample) | ||
| JP2024541969A5 (enExample) | ||
| JP6198286B2 (ja) | 癌の処置のためのイソフラボノイド化合物および方法 | |
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| JP2021524835A (ja) | Ａｘｌキナーゼ阻害剤およびその使用 | |
| JP2019529518A5 (enExample) | ||
| JP2018529780A5 (enExample) | ||
| JP2019526560A5 (enExample) |